The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 43 | — | 20.1x | Near average | |
Growth | 78 | — | 5.6% | Above average | |
Quality | 56 | 1256.6% | 7.6% | Near average | |
Safety | 65 | 1.0x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
OnKure Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy OnKure Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The price forecast analysis for OnKure stock shows complete stability in the target price at $35 over the past 7 and 30-day periods, with a total absence of Dispersion as analysts (based on a limited sample) agree on this target. This consistency reflects significant optimism compared to the current price ($4.21), but it lacks new momentum or recent updated revisions, indicating a state of waiting for tangible clinical or financial results.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.